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Abstract
Objective
The reported prevalence of cognitive impairment remains similar to that reported in the pre-
antiretroviral therapy era. This may be partially artefactual due to the methods used to diag-
nose impairment. In this study, we evaluated the diagnostic performance of the HIV-associ-
ated neurocognitive disorder (Frascati criteria) and global deficit score (GDS) methods in
comparison to a new, multivariate method of diagnosis.
Methods
Using a simulated ‘normative’ dataset informed by real-world cognitive data from the obser-
vational Pharmacokinetic and Clinical Observations in PeoPle Over fiftY (POPPY) cohort
study, we evaluated the apparent prevalence of cognitive impairment using the Frascati and
GDS definitions, as well as a novel multivariate method based on the Mahalanobis distance.
We then quantified the diagnostic properties (including positive and negative predictive val-
ues and accuracy) of each method, using bootstrapping with 10,000 replicates, with a sepa-
rate ‘test’ dataset to which a pre-defined proportion of ‘impaired’ individuals had been added.
Results
The simulated normative dataset demonstrated that up to ~26% of a normative control pop-
ulation would be diagnosed with cognitive impairment with the Frascati criteria and ~20%
with the GDS. In contrast, the multivariate Mahalanobis distance method identified
impairment in ~5%. Using the test dataset, diagnostic accuracy [95% confidence intervals]
and positive predictive value (PPV) was best for the multivariate method vs. Frascati and
GDS (accuracy: 92.8% [90.3–95.2%] vs. 76.1% [72.1–80.0%] and 80.6% [76.6–84.5%]
respectively; PPV: 61.2% [48.3–72.2%] vs. 29.4% [22.2–36.8%] and 33.9% [25.6–42.3%]
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respectively). Increasing the a priori false positive rate for the multivariate Mahalanobis dis-
tance method from 5% to 15% resulted in an increase in sensitivity from 77.4% (64.5–
89.4%) to 92.2% (83.3–100%) at a cost of specificity from 94.5% (92.8–95.2%) to 85.0%
(81.2–88.5%).
Conclusion
Our simulations suggest that the commonly used diagnostic criteria of HIV-associated cog-
nitive impairment label a significant proportion of a normative reference population as cogni-
tively impaired, which will likely lead to a substantial over-estimate of the true proportion in a
study population, due to their lower than expected specificity. These findings have important
implications for clinical research regarding cognitive health in people living with HIV. More
accurate methods of diagnosis should be implemented, with multivariate techniques offering
a promising solution.
Introduction
Cognitive impairment is frequently reported in people living with HIV, apparently affecting
up to 50% despite antiretroviral therapy [1,2]. However, the prevalence of cognitive
impairment in demographically comparable HIV-uninfected control groups is also reported
to be up to 29–36% [3,4]. Such rates of cognitive impairment does not generally tally with clin-
ical experience and symptomatology [5,6]. suggesting that these high rates may be artefactual
as a consequence of the approach used to define cognitive impairment.
A frequently used method of defining cognitive impairment in HIV-disease is the HIV-
associated neurocognitive disorder (HAND) classification, also known as the ‘Frascati criteria’.
This defines an individual as having cognitive impairment if s/he scores one or more standard
deviations (SD) below the normative mean in two or more cognitive domains (with the nor-
mative means and SDs having generally been obtained from historic population datasets) [7].
Mild impairment is further subdivided into symptomatic and asymptomatic, with those in the
two groups classified as having ‘mild neurocognitive disorder’ [MND] and ‘asymptomatic neu-
rocognitive disorder’ [ANI], respectively. HIV-associated dementia, the most severe form of
impairment, is defined when an individual scores two or more SDs below the normative mean
on tests from at least two cognitive domains with “marked impairment of day-to-day
functioning”.
A limitation of the classification of mild impairment (ANI/MND) is the false positive rate:
based on this definition and assuming scores follow a normal distribution, approximately 16%
(about 1 in 6) of a normative population would be expected to score one SD below the norma-
tive mean in any of the tests that are performed, even in the absence of any genuine
impairment. However, cognitive impairment is rarely diagnosed on the basis of a single test
from a single cognitive domain, with assessments of cognitive function usually including mul-
tiple tests from multiple different cognitive domains (typically six or seven). Thus, it is highly
likely that an individual would be classified as cognitively impaired simply by chance alone.
For example, a six domain model of cognitive function testing [3,6] is akin to rolling six dice
where each die represents a single fully independent cognitive domain and where a score of
‘one’ is indicative of a value that is>1 SD below the mean. In this case, the expected prevalence
of impairment (rolling ‘one’ in at least two of the six dice) is approximately 25%. However, an
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individual’s performance on different tests of cognition will be correlated, hypothesised to be
related to underlying latent factors e.g. general intelligence factor (‘g’) [8]. If cognitive tests are
perfectly correlated the probability of cognitive impairment in a normative population is the
same as if there was only one test i.e. 16%. However, in a more realistic situation with inter-test
correlation coefficients between zero and one, the ‘expected’ prevalence of ‘cognitive
impairment’ in a normative population will always exceed 16% [9]. Moreover, this inflated
prevalence of ‘cognitive impairment’ would be expected to increase with the number of tests
performed if no attempt is made to account for multiple comparisons. This may explain the
high reported prevalence of cognitive impairment (30–50%) in HIV-positive cohorts.
An alternative scoring system, known as the global deficit score (GDS), is obtained by con-
verting demographically adjusted test data to deficit scores, averaging them and using a pre-
specified threshold (a score0.5) to define as impairment [10]. The purpose of converting
demographically adjusted test scores to deficit scores is to attach more weight to impaired per-
formance with less weight placed on scores that are close to, or above, the mean, which could
counter-balance impairment if a simple averaging approach across cognitive domains was
used. This method aims to be most comparable to clinician rating, the purported ‘gold stan-
dard’, and has been shown to have good predictive and discriminatory power in HIV-positive
individuals [10]. Furthermore, by averaging over domains it is less affected by multiple com-
parisons and may be more reliable in terms of test-retest reliability. Considering the ‘expected
prevalence’ of impairment in a normative population, if the cognitive tests are perfectly corre-
lated, to have a GDS0.5, the score must be at least one SD below the mean to score a point
(no half points are awarded) and therefore the probability of impairment in this scenario is
~0.16 or 16%. If the tests are not correlated, then it is much more complicated as there are
many ways to achieve a GDS0.5 (e.g. if testing six domains having a deficit score of three in
one domain only or having three domains with a deficit score of only one).
Another method, known as the multivariate normative comparison (MNC), uses a study
specific control group as a reference to calculate a multivariate statistic (Hotelling’s T2) taking
into account performance in all cognitive domains and the covariance between tests [11]. As
only one statistical test is performed there is no multiple testing. For the diagnosis of HIV-
associated cognitive impairment, this method has been shown to potentially optimise the bal-
ance between sensitivity and specificity in the absence of a true gold standard [3]. One poten-
tial disadvantage of this method is that the relative measure of cognitive impairment provided
will depend on the availability and characteristics of the study specific control group–thus, if
the study group is compared to a different control group, the relative prevalence of cognitive
impairment may change. This contrasts with the Frascati criteria or GDS, which rely on nor-
mative means from historical datasets. These are likely to be more comparable between differ-
ent studies (cognitive batteries and differences in study populations notwithstanding) as the
reference group generally remains stable.
At its core, identifying cognitive impairment is akin to outlier detection, namely is this per-
son’s cognitive function below what is expected? For unidimensional data, such as height, the
probability of being x number of SDs from the mean can be inferred from the z-distribution.
For multidimensional data, such as testing cognitive function with several neuropsychological
tests, a multidimensional measure of deviation from the mean is needed–the Mahalanobis dis-
tance. Introduced in 1927, to study racial differences in anthropometrics, this statistic can be
thought of as a multivariate SD taking into account the covariance between different tests and
is related to the Hotelling’s T2 statistic used in the MNC [12]. Its major limitations are the
assumptions of multivariate normality and equal weighting for all variables. Like MNC, this
method is not biased by the number of tests performed and is robust to varying correlations
between tests. However, in contrast to the MNC method, the Mahalanobis distance can be
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calculated from the centre of a hypothetical normal population with the same inter-domain
correlations as the study population. Therefore, a study-specific control group, although desir-
able, is not required and prevalences may potentially be compared more fairly between studies.
The critical threshold below which participants are defined as having impairment, which for a
normally distributed population can be thought of by chance alone, can be fixed a priori at an
acceptable rate (e.g. the bottom 5th percentile). Therefore, rates above this (i.e. >5%) in a study
population would indicate a prevalence that is higher than can be expected by chance alone.
In this paper, we use a simulated dataset informed by real-world cognitive data from the
Pharmacokinetic and Clinical Observations in PeoPle Over fiftY (POPPY) study, to assess the
performance of several different commonly used approaches to define cognitive impairment,
and to compare these to a proposed new multivariate method based on Mahalanobis distance.
Methods
Participants
The POPPY study (ClinicalTrials.gov Identifier: NCT01737047, EudraCT Number: 2012-
003581-40) is a multi-centre, prospective cohort study primarily investigating the effects of
ageing and comorbidities in HIV-positive individuals in the UK and Ireland. For these analy-
ses, participants were prospectively enrolled into the POPPY study at seven sites across the
UK. Inclusion and exclusion criteria have been described previously [5,6]. For the purposes of
this analysis only HIV-positive and HIV-negative participants aged>50 were included.
All participants provided written informed consent. The study was approved by the UK
National Research Ethics Service (NRES; Fulham, London, UK—reference number 12/LO/
1409).
Cognitive function testing
All participants underwent cognitive function testing using a computerised battery (CogState™,
CogState Ltd, Melbourne, Australia) covering six cognitive domains including visual learning,
psychomotor function, visual attention, executive function, verbal learning and working mem-
ory (see Table 1 for details of tests performed and how they map to each cognitive domain) as
previously described [5,6]. This has been shown to be a sensitive diagnostic tool for the assess-
ment of HIV-associated CI and allows standardised assessment across sites to be completed in
a reasonable amount of time [13,14].
Table 1. Cognitive tests administered in the POPPY study by cognitive domain with data transformations.
Cognitive domain Test administered Scoring system
Attention/Working Memory One back task Arcsine root-proportion correct
Two back task Arcsine root-proportion correct
Executive Function Groton Maze Learning test Total errors
Set shifting task Total errors
Processing speed Detection task Log reaction time (ms)
Visual Attention Identification task Log reaction time (ms)
Verbal Learning/Memory International Shopping list task Total correct
International Shopping list task–delayed recall Total correct
Visual Learning/Memory Continuous paired associate learning test Total errors
Groton Maze Learning test–delayed recall Total errors
One card learning task Arcsine root-proportion correct
https://doi.org/10.1371/journal.pone.0194760.t001
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Raw test scores were log-transformed or arcsine root–transformed where necessary (as rec-
ommended by the CogState guidelines for analysis) and converted into demographically-
adjusted T-scores (with a mean of 50 and a standard deviation of 10) using the HIV-negative
control group as the reference population. This method was used as the CogState norms do
not cover the age range of the participants in our study. These adjusted T-scores took into
account age, level of education, gender and ethnicity as appropriate. A single T-score was cal-
culated for each of the 6 cognitive domains by averaging individual T-scores within each
domain. A global T-score was also obtained by averaging across the six domains. For all T-
scores, higher scores indicate better cognitive function. Data integrity and quality checks were
applied to ensure that scores were generated from completed and fully-understood tasks for
each subject. Individual test scores not meeting integrity and quality checks were excluded.
Multivariate assessment of cognitive impairment
This method is related to the MNC method described by Huizenga et al,[11] however it does
not necessarily require a study-specific control group. To estimate the measure, a matrix of
correlation coefficients of the study sample’s cognitive data is first calculated. Next, for each
subject, the Mahalanobis distance is calculated from a hypothetical control population in
which the cognitive data are assumed to follow a multivariate normal distribution with known
means and covariance. For T-scores, the normative mean is 50 and SD is 10 for each domain.
The population covariance is estimated from the study sample (or control group) by convert-
ing the previously calculated correlation matrix into a covariance matrix. The Mahalanobis
distance is then calculated for each study participant. As the Mahalanobis distance has magni-
tude and not direction, it cannot be assumed that larger values correspond to more severe cog-
nitive impairment. Thus, to provide direction, the sign of the difference between the global T-
scores (i.e. the means of the domains) of the subject and the population mean are applied to
the Mahalanobis distance, so that positive values represent scores in general that are above the
mean and negative values represent scores below (i.e. impairment). To determine impairment
each subject’s signed Mahalanobis distance is then compared to a critical value.
The critical value can be determined mathematically in two ways, depending on whether
the study sample is used to estimate the comparator covariance or if this is determined from
an independent reference population (i.e. a control group). In the first instance, the distribu-
tion of the squared Mahalanobis distance from the independent multivariate mean approxi-
mates the F distribution and the following formula can be used:
critical value ¼  
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
F a; p;n  p  pðn   1Þðnþ 1Þ
nðn   pÞ
s
Where:
n = the number of subjects.
p = the number of domains/tests.
F = the critical value from the F distribution with p and n-p degrees of freedom with α =
0.05 (i.e. corresponding to the bottom 5th percentile of a normative population).
If no control group is present, or if the assessment of impairment of members of the control
group is to be performed, then each study participant’s Mahalanobis distance will be calculated
from the hypothetical control population. To accomplish this, the study observations are used
to estimate the covariance for the hypothetical control population. In this case, the squared
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Mahalanobis distance approximates the β distribution and the following formula can be used:
critical value ¼  
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
ðn   1Þ2
n
 b
a ;
p
2
;
ðn  p  1Þ
2
s
Where:
n = the number of subjects
p = the number of domains/tests
β = the critical value from the β distribution with parameters p
2
and ðn  p  1Þ
2
with α = 0.05
(i.e. corresponding to the bottom 5th percentile of a normative population)
These formulae are derived from the equations described by Maesschalck et al [12] taking
account of the signing process to determine the direction of deviation from the norm and that the
base formulae relate to the squared Mahalanobis distance. It should be noted that the first equa-
tion using the F distribution is very similar to that described for the MNC between two groups
described by Huizenga et al [11]. Further, they are only appropriate in the context of a multivari-
ate normal distribution (i.e. not significantly skewed/transformed, in which case simulated data
and bootstrapping may be more appropriate). Note, where the number of subjects (n) greatly
exceeds the number of tests (p) and is large (>200) these methods converge, e.g. for n = 100,000,
the critical values are -3.2626 and -3.2628 using the β distribution and F distribution (Fig 1).
Testing the definitions of cognitive impairment
As no gold standard exists for the diagnosis of HIV-associated cognitive impairment, perfor-
mance of different definitions of cognitive impairment was assessed using simulation
informed by real world data. Firstly, the inter-domain correlation coefficients were calculated
for both the HIV-positive and HIV-negative groups from the POPPY study. Steiger’s method
[15] was used to assess whether the resulting correlation matrices differed between groups.
Next, data were simulated for a hypothetical normative ‘control’ population with normally dis-
tributed (mean T-score: 50; SD: 10) cognitive scores across six domains using the ‘mvrnorm’
command in the MASS [16] package of R. These simulated data therefore followed a multivari-
ate normal distribution with inter-domain correlations set to replicate the HIV-positive group
from the POPPY study. As a study population invariably involves sampling a subset from the
entire population, the sample prevalence of cognitive impairment only approximates the pop-
ulation prevalence when n is large. Therefore, a sample (n = 290) was drawn from the simu-
lated normative control population. The Frascati criteria [7], GDS [10] using the threshold of a
mean deficit score0.5 to signify impairment and multivariate method outlined above were
then applied to calculate the sample prevalence of cognitive impairment for each approach.
Next, an ‘impaired’ population was added to this hypothetical normative control population
to create a ‘test dataset’. The ‘impaired’ population were assumed to have a mean T-score of 30
and SD of 10 and thus is comparable to the inclusion of a group of patients with HIV-associated
dementia (scores of two SDs or more below the normative mean in 2 or more tests/domains)
[7]. The prevalence of ‘impairment’ (i.e. the size of the ‘impaired’ population that was added)
was initially set at 10%. Inevitably there is some overlap between those who are labelled as
impaired and those on the lower end of the normal distribution. This is likely to be the case in
real life, whereby an individual with above average cognitive performance who sustains a brain
injury may subsequently perform at an average level.
To assess performance the sensitivity, specificity, predictive value and accuracy were deter-
mined by comparing the subjects diagnosed as impaired by each method to the subjects with
‘true’ impairment (true positives). Bootstrapping was performed (10,000 repetitions with
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replacement) to determine the mean prevalence of cognitive impairment and performance
characteristics with 95% confidence intervals. Additionally, separate simulations were per-
formed with different critical values for the Mahalanobis distance method, corresponding to
the bottom 10th and 15th percentiles of a normative population. As a final step, the prevalence
of true impairment was varied from 0–40% by increasing the size of the ‘impaired’ sample, and
the previous steps were repeated.
To provide a clear illustration of the approach, an interactive web-based simulation with
adjustable parameters can be found here:
https://jonathan-underwood.shinyapps.io/cognitive_impairment_comparison/
In addition, a web-based tool, where users can upload data and perform standard and mul-
tivariate analyses is provided here:
https://jonathan-underwood.shinyapps.io/cognitive_calculator/
Fig 1. Convergence of the critical value to determine cognitive impairment as the sample size increases. This model assumes a six test/domain model. The critical
value from simulated data was the mean of 100 replicates.
https://doi.org/10.1371/journal.pone.0194760.g001
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Initial collation and analysis of cognitive data was performed using SAS v9.4 (SAS Institute
Inc., Cary, NC, USA). All simulations were performed using R v3.2.4 (R Foundation for Statis-
tical Computing, Vienna, Austria) with the ‘MASS’ package v7.3–45. The code for these simu-
lations can be found in the supporting information (S1 File). Only P-values (two-sided) <0.05
were considered statistically significant.
Results
The inter-domain correlation coefficients for the POPPY HIV-positive group ranged from
r = 0.05 for processing speed and verbal learning/memory to r = 0.60 for executive function
and processing speed (Fig 2). The inter-domain correlation matrices did not differ signifi-
cantly between the HIV-positive and HIV-negative control groups (χ215 = 19.5, p = 0.19). The
prevalence of cognitive impairment (95% confidence intervals) in the ‘normative’ control pop-
ulation informed by this data was 25.8% (21.7–30.0%) for Frascati; 20.6% (16.9–24.5%) for
GDS and 5.0% (3.1–7.2%) for the multivariate Mahalanobis distance method.
When this simulated dataset was enriched with an ‘impaired’ sub-population to create the
‘test’ dataset, comprising 10% of the total (Fig 3A for a graphical illustration), the prevalence of
cognitive impairment increased to 33.6% (29.3–38.3%) using the Frascati criteria (Fig 3B);
28.5% (24.8–32.8%) for GDS (Fig 3C); and 12.1% (9.0–15.1%) for the multivariate Mahalano-
bis distance method (Fig 3D and Table 2 for performance diagnostics). Accuracy was best for
the Mahalanobis distance method (92.8% [90.3–95.2%] vs. 76.1% [72.1–80.0%] for Frascati
and 80.6% [76.6–84.5%] for the GDS). Accuracy was non-significantly improved using a defi-
nition of impairment whereby participants had to be identified by all three definitions over the
Mahalanobis distance method on its own (93.6% [91.0–95.9]).
Fig 2. Comparison of the cognitive domain correlation matrices for the HIV-positive and HIV-negative control groups from the POPPY study. Visualisation of the
inter-domain correlation matrices for the HIV-negative (panel a) and HIV-positive (panel b) participants of the POPPY study. Colour scale determined by Pearson’s r
(scale to the right of the figure).
https://doi.org/10.1371/journal.pone.0194760.g002
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Reducing the critical value used to define impairment using the Mahalanobis distance
method resulted in higher sensitivity at a cost of specificity (Table 3). However, accuracy was
Fig 3. Histograms of a simulated study population with a 10% prevalence of cognitive impairment. Panel a) 90% of the population are ‘normal’ and have a mean
(standard deviation) T-score of 50 (10)–red. 10% of the population are impaired and have a mean T-score of 30 (10). Panels b-d: how the population is labelled by method
used to define impairment.
https://doi.org/10.1371/journal.pone.0194760.g003
Table 2. Performance of three definitions of cognitive impairment in a simulated population with a 10% prevalence of cognitive impairment.
Criteria Sensitivity (95% CI) Specificity (95% CI) PPV
(95% CI)
NPV
(95% CI)
Accuracy
(95% CI)
Frascati 98.7% (94.7–100%) 73.5% (69.0–78.0%) 29.4% (22.2–36.8%) 99.8% (99.1–100%) 76.1% (72.1–80.0%)
Global deficit score 98.2% (93.3–100%) 78.7% (74.4–82.7%) 33.9% (25.6–42.3%) 99.7% (99.0–100%) 80.6% (76.6–84.5%)
Mahalanobis distance 77.4% (64.5–89.4%) 94.5% (92.8–95.2%) 61.2% (48.3–74.2) 97.4% (95.7–98.8%) 92.8% (90.3–95.2%)
Combination of all three 77.4% (64.5–89.5%) 95.4% (93.2–97.3%) 65.2% (51.6–78.4%) 97.4% (95.7–98.8%) 93.6% (91.0–95.9%)
https://doi.org/10.1371/journal.pone.0194760.t002
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still superior to the Frascati and GDS methods of defining impairment with a threshold set to
the bottom 15th percentile of a normative population.
When the prevalence of impairment was 5% in the test dataset, the positive predictive value
of true cognitive impairment was below 25% for the Frascati and GDS compared with nearly
50% for the Mahalanobis distance method (Fig 4). As expected, as the prevalence of impairment
increased in the test dataset the positive predictive value increased for all three methods, but
was significantly higher for the Mahalanobis distance method across the range of prevalences
tested (5–40%).
Discussion
Here, we have shown the utility of using a simulated dataset to test the performance charac-
teristics of two commonly used methods of defining HIV-associated cognitive impairment.
Using real-world cognitive data to inform our multivariate model, the Frascati and GDS
methods would classify over 20% of a normative control population as impaired. Using the
Table 3. Performance of five definitions of cognitive impairment in a simulated population with a 10% prevalence of cognitive impairment.
Criteria Sensitivity (95% CI) Specificity (95% CI) PPV
(95% CI)
NPV
(95% CI)
Accuracy
(95% CI)
Frascati 98.7% (94.7–100%) 73.5% (69.0–78.0%) 29.4% (22.2–36.8%) 99.8% (99.1–100%) 76.1% (72.1–80.0%)
Global deficit score 98.2% (93.3–100%) 78.7% (74.4–82.7%) 33.9% (25.6–42.3%) 99.7% (99.0–100%) 80.6% (76.6–84.5%)
Mahalanobis distance (alpha 5%) 77.4% (64.5–89.4%) 94.5% (92.8–95.2%) 61.2% (48.3–74.2) 97.4% (95.7–98.8%) 92.8% (90.3–95.2%)
Mahalanobis distance (alpha 10%) 87.8% (77.1–96.7%) 90.0% (86.9–93.0%) 49.5% (38.0–61.1%) 98.5% (97.1–99.6%) 89.8% (87.0–92.8%)
Mahalanobis distance (alpha 15%) 92.2% (83.3–100%) 85.0% (81.2–88.5%) 40.6% (30.9–50.7%) 99.0% (97.9–100%) 85.7% (82.4–89.0%)
https://doi.org/10.1371/journal.pone.0194760.t003
Fig 4. Positive predictive value of each diagnostic method by prevalence of impairment in the simulated study population.
https://doi.org/10.1371/journal.pone.0194760.g004
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multivariate approach described here, this can be limited to any predetermined level and
has demonstrably superior accuracy and positive predictive value.
Standard deviations are useful when dealing with one dimensional, normally distributed
data. However, with correlated multivariate data, they are less useful and arguably inappropri-
ate. This is particularly true if there is no stipulated maximum number of tests that a given cri-
terion is applied to. Therefore, it is not unsurprising, given the methodology of both the
Frascati criteria and GDS, that such a large proportion of a normative control population are
classified as impaired by chance alone. Comparable prevalences of cognitive impairment have
been reported in HIV-negative control groups (36% [3] and 29% [4]) of two recent studies.
Similarly, McDonnel et al [4] reported impairment in 27% of their HIV-negative control
group using the GDS. As we have demonstrated, these estimates are similar to what would be
expected by chance. Our findings potentially have relevance in other fields (and could be easily
applied to any non-cognitive multivariate data). For example, ageing-associated cognitive
decline (AACD) uses a similar definition as the Frascati criteria to determine impairment. A
study [17] in a healthy elderly population identified AACD in 26.6%—a figure that would be
expected by chance as demonstrated here.
It should be noted that comparing neuropsychological test scores to a numerical threshold
is not the sole arbiter of whether a patient is labelled as cognitively impaired or not. It is imper-
ative that potentially confounding comorbidities and functional status are also taken into
account. It is also essential to understand the properties of any statistical procedure that is used
to determine abnormal performance. As demonstrated here, the Frascati definition of abnor-
mal testing will label about a quarter of a healthy reference population as cognitively impaired.
This is in agreement with previous work by Taylor & Heaton[18] who found that to maintain
specificity with a six domain battery, impairment of>1SD in three or more domains would be
necessary. Given that asymptomatic impairment has by definition no functional impact, a
quarter of the normative reference population will therefore meet the criteria for ANI. There-
fore, even if HIV is not associated with any degree of brain injury one would expect ~25% to
be labelled as having ANI (and ~2% to meet the neuropsychological testing criteria for HIV-
associated dementia) by chance variation alone. These high estimates of HIV-associated cogni-
tive impairment are problematic for several reasons. Firstly, without a control group for com-
parison, the prevalence of impairment may be substantially over interpreted, with assumptions
made about a causal impact of HIV on cognition. Secondly, such misclassification may hamper
studies of the pathophysiology of disease, as many individuals may have been labelled as
impaired by chance alone, leading to a reduced ability and power to detect associations with
other measures of interest (e.g. soluble biomarkers associated with specific pathogenic pro-
cesses). Thirdly, the use of these methods as either inclusion criteria or as outcome measure,
may reduce the ability of a clinical trial to demonstrate a beneficial effect of an intervention.
Finally, if such research methods are used in clinical practice to identify patients with cognitive
impairment, it may lead to unnecessary anxiety in those who are falsely labelled as having
impairment and may prompt unnecessary further investigations or treatment. Hence there is a
need for a robust method of defining cognitive impairment which will not over-inflate the
false positive rate.
For the purposes of determining the pathophysiology of HIV-associated cognitive
impairment, it may be advantageous to use continuous measures of cognitive function.
Dichotomising data into two groups for statistical analysis has many drawbacks [19].
Firstly, given the distribution of most cognitive data, the assumption there are two clear
groups is probably not valid. Furthermore, the difference between those with and without
impairment at the margin, is greatly exaggerated. Secondly, as up to a third of information
is lost [19], statistical power is reduced which may lead to false conclusions being drawn.
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With these shortcomings, it is worth considering why a standardised definition of cogni-
tive impairment is required. Scientific curiosity aside, the purpose of a definition is gener-
ally to aid the treatment of disease. At some point a yes/no or impaired/not impaired
decision must be made and thus dichotomised cognitive function data is desirable. The
motivation for updating the HIV-associated neurocognitive disorders classification, to
create the so-called Frascati criteria, was to improve standardisation by introducing clear
definitions of what was considered abnormal and to include a category of asymptomatic
impairment [7]. Prior to this update in 2007, the study of HIV-associated cognitive
impairment focused on severe dementia, the prevalence of which declined dramatically
with the advent of antiretroviral therapy. At the time the HAND criteria were proposed
they took into consideration the changing phenotype of cognitive disorders in HIV-dis-
ease. This category of mild impairment, without deficit in performance in everyday activi-
ties, was thought to be a possible precursor to more severe impairment. Consequently,
identification of patients in this group was considered important as subsequent interven-
tion may prevent further decline. However, the evidence that these mild forms of cogni-
tive impairment progress is mixed and the data that do suggest an increased risk of
functional impairment longitudinally were in populations with inadequate suppression of
HIV-replication [20–23]. Nearly a decade after its introduction, the phenotype of HIV-
associated cognitive disorders is again changing as antiretroviral therapy has improved
and patients are ageing. Our simulation data suggests that this definition, as it stands, is
insufficiently stringent, with many patients being labelled as impaired by chance. The
GDS method represents a slight improvement, but still labels approximately 20% of a nor-
mative control population as impaired. A potentially better, albeit slightly more compli-
cated, method using the multivariate Mahalanobis distance allows the false positive rate to
be controlled at any desired level. As can be seen in table three, increasing the false posi-
tive rate (alpha) from 5% to 15% and therefore decreasing the specificity from 95% to
85%, results in an increase in sensitivity at a cost of accuracy. Choosing the optimal
threshold requires a compromise between false positive and false negative tests, but in
general the specificity should be high, sensitivity and specificity should be balanced and
accuracy should be high as possible. [18] The optimal false positive rate for the study of
HIV-associated cognitive impairment is unknown but could be tested in future studies
using neuroimaging and CSF biomarkers of brain injury. One potential limitation of this
method is that the covariance between cognitive domains is estimated from the patient
group, which may differ from a control group. However, whilst having a control group is
preferable, the correlation matrices between patient and control groups did not differ sig-
nificantly in the POPPY study, justifying this approach. Another potential limitation of
this model is that it is based on inter-domain correlations obtained from study data where
participants were tested using the CogState™ battery, which has not been externally or
clinically validated for its embedded cognitive constructs. Further study of this novel defi-
nition of cognitive impairment in other cohorts, where different neuropsychological test
batteries have been used are warranted. Furthermore, the associations between neuroim-
aging and CSF biomarkers and this definition of cognitive impairment are needed to
assess whether tighter associations between pathogenic mechanisms are observed more
consistently than with previous methods. Web-based tools are provided to illustrate the
approach and allow it to be easily applied to other datasets:
https://jonathan-underwood.shinyapps.io/cognitive_impairment_comparison/ and https://
jonathan-underwood.shinyapps.io/cognitive_calculator/.
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Conclusion
The commonly used diagnostic criteria for HIV-associated cognitive impairment do not
account for the correlation structure known to exist across cognitive tests. Our simulations
show that they label a significant proportion of a normative reference population as cognitively
impaired, which will likely lead to a substantial over-estimate of the true proportion in a study
population, due to their lower than expected specificity. These findings have implications for
future research. More statistically appropriate methods of diagnosis should be considered,
with multivariate techniques offering a promising solution.
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